Related references
Note: Only part of the references are listed.An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis
Andrea Necchi et al.
EUROPEAN UROLOGY (2019)
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
Neil H. Segal et al.
EUROPEAN JOURNAL OF CANCER (2019)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg et al.
EUROPEAN JOURNAL OF CANCER (2019)
Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines
Saralinh Trinh et al.
ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING (2019)
Immunological Agents Used in Cancer Treatment
Melih Simsek et al.
EURASIAN JOURNAL OF MEDICINE (2019)
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
Shuguang Tan et al.
PROTEIN & CELL (2018)
Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Brandon W. Higgs et al.
CLINICAL CANCER RESEARCH (2018)
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
Hui Yang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
Luana Calabro et al.
LANCET RESPIRATORY MEDICINE (2018)
Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay
Paul Scorer et al.
DIAGNOSTIC PATHOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Fatima Karzai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung-Min Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Hyun Tae Lee et al.
SCIENTIFIC REPORTS (2017)
irRECIST and iRECIST: the devil is in the details
J. Le Lay et al.
ANNALS OF ONCOLOGY (2017)
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1
Marisa Dolled-Filhart et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Microsatellite Instability as a Biomarker for PD-1 Blockade
Jonathan C. Dudley et al.
CLINICAL CANCER RESEARCH (2016)
Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial
Antonin Levy et al.
EUROPEAN JOURNAL OF CANCER (2016)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
Ross Stewart et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation
Simone P. Sittig et al.
BIOMEDICINES (2015)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Share Paper
